Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




White Cell Count Predicts Kidney Disease Prognosis

By LabMedica International staff writers
Posted on 12 Jun 2011
The number of lymphocytes in the blood is a possible prognostic indicator for renal cell carcinoma (RCC).

The lymphocytes are one of the types of white blood cells that are routinely enumerated in clinical laboratories and the low counts may be indicative of a suppressed immune system.

Medical oncologists at the Fox Chase Cancer Center, (Philadelphia, PA, USA), evaluated data from more than 500 patients with the most common form of RCC, called clear cell RCC, who had their kidneys surgically removed at Fox Chase between 1994 and 2009. More...
They found a clear relationship between low lymphocyte counts within three months prior to surgery and a poor prognosis.

The scientists found that lower lymphocyte levels were associated with a higher tumor grade, a higher pathologic tumor stage, the presence of distant metastases, and a higher classification of malignant tumors (TNM) stage, which is a combined indicator of tumor stage, spread to regional lymph nodes, and distant metastasis. They also found that low counts were associated with a lower overall survival rate, even when they accounted for patient age, tumor stage, and metastasis.

Sunil Saroha, MD medical oncology fellow at Fox Chase and lead author on the study, said, "There has been this need for looking at prognostic markers that are available prior to surgical procedures. It would be nice to know before the surgery if the tumor is going to be aggressive and how aggressive we need to be, with the goal of individualizing therapies." This simple test can really help identify patients at the outset who are at risk of very aggressive disease and who may not do well with current therapies.

Each year, kidney cancer is diagnosed in nearly 60,000 people in the US Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated. For example, if a young RCC patient does not have a low lymphocyte count, and is otherwise healthy, a doctor may decide not to pursue the more aggressive therapies, such as surgery and chemotherapy. The study will be presented at the Annual Meeting of the American Society of Clinical Oncology on June 5, 2011 in Chicago (IL, USA).

Related Links:

Fox Chase Cancer Center




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.